Antisense Therapeutics Limited (ASX:ANP)
ASX Junior’s Flagship Immunomodulatory Drug Could Turn the Tide in Duchenne Muscular Dystrophy Treatment
Oct 16, 2018
Duchenne muscular dystrophy (DMD) is a rare, yet fatal, muscular genetic condition that affects one in 3600 to 6000 male births worldwide. This ASX junior, capped at just $7 million, is already in a Phase II clinical trial with its flagship drug to treat DMD.
The Next Big Thing in Nickel? ASX Newcomer Partners Up with World’s Biggest Stainless Steelmaker
Jan 15, 2019
Diversified ASX Junior Next Door to Fortescue May Have a Major Australian Gold Asset
Jan 14, 2019